Johnson & Johnson posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations ...
Johnson & Johnson (JNJ) said the company expects fiscal 2025 adjusted EPS in a range of $10.50 - $10.70, which represents a growth of ...
Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...
Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its ...
As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...
Prism Johnson Ltd., incorporated in the year 1992, is a Mid Cap company (having a market cap of Rs 7,541.79 Crore) operating in Cement sector. Prism Johnson Ltd. key Products/Revenue Segments include ...